Veracyte, Inc. (VCYT)
Market Cap | 1.63B |
Revenue (ttm) | 375.47M |
Net Income (ttm) | -68.18M |
Shares Out | 76.45M |
EPS (ttm) | -0.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 574,463 |
Open | 21.37 |
Previous Close | 21.33 |
Day's Range | 21.10 - 21.73 |
52-Week Range | 18.61 - 30.52 |
Beta | 1.70 |
Analysts | Buy |
Price Target | 27.50 (+29.35%) |
Earnings Date | Aug 6, 2024 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy... [Read more]
Financial Performance
In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 29.35% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/u/z/press8-2460047.jpg)
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors.
![](https://cdn.snapi.dev/images/v1/8/p/press17-2444304.jpg)
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.
![](https://cdn.snapi.dev/images/v1/c/b/conf3-2433615.jpg)
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences. Leerink Par...
![](https://cdn.snapi.dev/images/v1/w/k/press1-2416184.jpg)
Veracyte Announces First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong start to 2024, driven by robu...
![](https://cdn.snapi.dev/images/v1/s/c/press8-2413139.jpg)
14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients.
![](https://cdn.snapi.dev/images/v1/x/9/conf19-2384303.jpg)
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, M...
![](https://cdn.snapi.dev/images/v1/s/k/press3-2382992.jpg)
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance.
![](https://cdn.snapi.dev/images/v1/i/d/press2-2373374.jpg)
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024.
![](https://cdn.snapi.dev/images/v1/x/o/press12-2297285.jpg)
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.
![](https://cdn.snapi.dev/images/v1/b/m/press10-2289717.jpg)
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. “We closed 2023 with another...
![](https://cdn.snapi.dev/images/v1/a/y/press10-2287272.jpg)
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will pres...
![](https://cdn.snapi.dev/images/v1/n/4/conf6-2266822.jpg)
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market o...
![](https://cdn.snapi.dev/images/v1/w/u/press12-2261867.jpg)
Veracyte Completes Acquisition of C2i Genomics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes Acquisition of C2i Genomics.
![](https://cdn.snapi.dev/images/v1/v/8/press6-2220047.jpg)
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary unaudited financial results for the fourth quarter and fu...
![](https://cdn.snapi.dev/images/v1/j/t/press14-2193718.jpg)
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will present at t...
![](https://cdn.snapi.dev/images/v1/1/b/press12-2180521.jpg)
Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight ...
![](https://cdn.snapi.dev/images/v1/s/q/press2-2175802.jpg)
Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Clinical Validation Data for Veracyte's Percepta Nasal Swab Test Published in CHEST.
![](https://cdn.snapi.dev/images/v1/h/u/press8-2168733.jpg)
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 202...
![](https://cdn.snapi.dev/images/v1/o/p/press3-2145217.jpg)
Veracyte Announces Third Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Third Quarter 2023 Financial Results.
![](https://cdn.snapi.dev/images/v1/p/r/press5-2145509.jpg)
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally.
![](https://cdn.snapi.dev/images/v1/o/l/press10-2135971.jpg)
Veracyte to Participate in the Stephens Annual Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Stephens Annual I...
![](https://cdn.snapi.dev/images/v1/7/g/press11-2125559.jpg)
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy...
![](https://cdn.snapi.dev/images/v1/e/u/conf13-2106468.jpg)
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2023 after the close of market on Tuesday, N...
![](https://cdn.snapi.dev/images/v1/l/n/press6-2100815.jpg)
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte's Envisia Genomic Classifier for Patients with Interstitial Lung Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate ...
![](https://cdn.snapi.dev/images/v1/7/r/press11-2090341.jpg)
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Cl...